The goal of this clinical trial is to improve diagnosis and treatment strategies for patients with Cancer of Unknown Primary (CUP) by using advanced molecular profiling to identify the likely tumor origin and guide therapy. The main questions it aims to answer are: Can comprehensive molecular profiling help determine the origin of CUP tumors? Does identifying the tumor origin improve treatment choices and survival outcomes compared to historical data? Participants will: * Undergo a new biopsy to collect tumor tissue for advanced analyses. * Provide blood samples for circulating tumor DNA (cfDNA/ctDNA) analyses. * Provide a fecal sample for microbiome analysis. * Have their tumor tissue analyzed using: Methylation profiling and comprehensive gene panel testing. * Have the results reviewed in a specialized CUP molecular MDT meeting to determine the likely tumor origin and guide treatment. * Have their tumor tissue samples biobanked for further exploratory whole genome sequencing (WGS) and RNA sequencing.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
350
A fresh frozen biopsy and blood plasma for cfDNA analyses is taken upon inclusion for comprehensive molecular profiling. Results are discussed at a study specific CUP molecular MDT meeting.
Haukeland University Hospital
Bergen, Norway
Akershus University Hospital
Oslo, Norway
Oslo University Hospital
Oslo, Norway
Stavanger University Hospital
Stavanger, Norway
University Hospital of North-Norway
Tromsø, Norway
St Olavs Hospital
Trondheim, Norway
Percentage of patients where the site of origin is identified
Site of origin identified is defined as the cases where the CUP molecular MDT concludes with a likely primary site of origin
Time frame: From enrollment to the conclusion at the CUP molecular MDT at 8 weeks
Percentage of patients where treatment choice differs from empirical CUP regimen
Organ specific treatment chosen over empirical CUP treatment, based on the conclusion from the CUP MDT
Time frame: From conclusion at the CUP molecular MDT to the start of subsequent treatment within a timeframe of 36 months from study inclusion
Progression free survival
The length of time from the start of treatment until disease progression or death from any cause, whichever occurs first.
Time frame: From the date of first administration of a treatment line to the date of progression or death, or censored if alive at time of analysis, with a timeframe of 36 months from study inclusion.
Overall survival
Length of time from CUP diagnosis until death from any cause
Time frame: From date of CUP diagnosis until death from any cause or censored if alive at date of analysis, within a timeframe of 36 months from study inclusion.
Identification of tumor site using molecular profiling methods
The percentage of patients in whom the likely site of origin is identified by each molecular profiling method.
Time frame: From study enrollment to the conclusion at the CUP molecular MDT at 8 weeks
Incidence of molecular alterations and use of targeted treatment in CUP patients
The frequency of molecular alterations and actionable targets in patients with CUP, and the percentage of patients receiving targeted therapy based on molecular profiling results. The impact of targeted treatment on survival will also be evaluated.
Time frame: From molecular profiling to initiation of targeted therapy and follow-up for survival outcomes, within a timeframe of 36 months from study inclusion.
Impact of CUP molecular MDT assessement on previous clinical work-up
This outcome evaluates the utility of CUP molecular MDT meetings by measuring the percentage of patients for whom additional clinical work-up or pathology analyses are recommended and the concordance between local and study pathologist conclusions.
Time frame: From enrollment until CUP mol MDT at 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.